# Bota Biosciences (HK)

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bota-biosciences-hk

- Industry: Biotechnology
- Headquarters: Hangzhou, China
- Website: www.bota.bio
- Total disclosed funding: $115M
- Latest round: Series B (Jul 29, 2021)
- Investors on record: 7

## About

Based in Hangzhou, China, and founded in 2019, Bota Biosciences (HK) Limited operates as an industrial biotechnology company that focuses on synthetic biology via utilizing machine learning technology. The company's main business is in Boston, California, and Hangzhou. Bota Biosciences was founded by Cheryl Cui and is backed by Sequoia Capital, Matrix Partners China, Sherpa Venture Capital, and raised USD 100 million in Series B funding.

Bota Biosciences develops a technology platform known as the Bota Freeway, which combines advanced digital tools with lab automation. The company focuses on the development of high-efficiency, green, low-cost, and suitable for large-scale production of industrial biological manufacturing technology through the use of standardized and automated high-throughput wet experimental platforms (Bio-foundry).

The company plans to expand its global operations and build out its lab-to-pilot scale platform.

## Funding rounds

- Series B, Jul 29, 2021, $100M — Hong Shan, 5Y Capital, Source Code Capital, MPC, Sherpa Healthcare Partners
- Series A, Sep 25, 2020, $15M — Baidu Ventures, MPC, Sherpa Healthcare Partners
- Seed, Sep 2, 2019 — Nest.Bio Ventures

## Investors

- Nest.Bio Ventures (https://capitalatlas.ai/funds/nest-bio-ventures) — Seed
- Baidu Ventures (https://capitalatlas.ai/funds/baidu-ventures) — Series A
- MPC — Series A, Series B
- Sherpa Healthcare Partners (https://capitalatlas.ai/funds/sherpa-healthcare-partners) — Series A, Series B
- Hong Shan — Series B
- 5Y Capital (https://capitalatlas.ai/funds/5y-capital) — Series B
- Source Code Capital (https://capitalatlas.ai/funds/source-code-capital) — Series B